Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 108 Patriot Drive, Suite A MIDDLETOWN DE 19709 |
Tel: | N/A |
Website: | https://www.zymeworks.com |
IR: | See website |
Key People | ||
Kenneth H. Galbraith Chairman of the Board, President, Chief Executive Officer | Christopher Astle Chief Financial Officer, Senior Vice President | Paul A. Moore Chief Scientific Officer |
Business Overview |
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. It is also advancing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas with an emphasis on developing ADC and multi-specific antibody therapeutics (MSAT) candidates. Its pipeline of preclinical product candidates includes two lead programs, ZW191 and ZW17. |
Financial Overview |
For the fiscal year ended 31 December 2023, Zymeworks Inc revenues decreased 82% to $76M. Net loss totaled $118.7M vs. income of $124.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Stock-based Compensation in SGA increase from $1.2M to $5.3M (expense), Foreign exchange gain decrease from $1.2M (income) to $1.2M (expense). |
Employees: | 272 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $352.65M as of Dec 31, 2023 |
Annual revenue (TTM): | $76.01M as of Dec 31, 2023 |
EBITDA (TTM): | -$127.89M as of Dec 31, 2023 |
Net annual income (TTM): | -$118.67M as of Dec 31, 2023 |
Free cash flow (TTM): | -$122.38M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 71,219,441 as of Mar 4, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |